Clinical Trial Update: Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of Octagam 10% intravenous immunoglobulin for mild-to-moderate Alzheimer's disease has completed, with results posted in 2014. Sponsor: Octapharma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Octagam 10% (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Octapharma | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-05-05